NuVasive

Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer

Retrieved on: 
Monday, March 18, 2024
Medical Devices, Health, Hospitals, Surgery, General Health, Biotechnology, Inclusion, NuVasive, Bruker, Equity, Therapy, CHRO, Spine, Multimedia, Business operations, Elective surgery, Management

(NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240318931186/en/
    Lucas Vitale, appointed Chief People and Business Operations Officer at Orthofix (Photo: Business Wire)
    Vitale most recently served as the Chief Human Resources Officer (CHRO) at ReNAgade Therapeutics, a venture backed pharmaceutical company, and prior to that, he served as the CHRO at Berkeley Lights/PhenomeX, a life sciences tools and services company acquired by Bruker.
  • “We are pleased to welcome Lucas to our executive leadership team,” said Massimo Calafiore, President and Chief Executive Officer of Orthofix.
  • “In this pivotal role, he will lead the company’s ongoing integration and business transformation strategies as we continue to strengthen our infrastructure to support future growth.”
    “I am excited by the continued opportunities to bring Orthofix and SeaSpine together,” said Lucas Vitale, Chief People and Business Operations Officer.

Globus Medical Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Philosophy, Spine, Globus Medical, Telephone, ID, Surgeon, NuVasive, GAAP, Webcast, Patient, EPS, Globus, Pharmaceutical industry

AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.
  • U.S. net sales for the fourth quarter of 2023 increased by 111.1% compared to the fourth quarter of 2022. International net sales increased by 200.9% over the fourth quarter of 2023 on an as-reported basis, and an increase of 200.8% on a constant currency basis.
  • Diluted EPS for the fourth quarter was $0.11, compared to $0.49 for the fourth quarter of 2022.
  • Globus Medical will hold a teleconference to discuss its 2023 fourth quarter and full year results with the investment community at 4:30 p.m. Eastern Time today.

J. Kurt Jacobus, Ph.D. Joins CurvaFix Board of Directors

Retrieved on: 
Tuesday, March 5, 2024
Medical Devices, Health, Surgery, Other Health, General Health, Biotechnology, Acquisition, Champaign–Urbana metropolitan area, Bone fracture, Enovis, Mechanical, Foot, Doctor of Philosophy, Pelvis, NuVasive, University, Mechanical engineering, Patient, Anatomy, Science, Trauma, Research, Nursing

CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.

Key Points: 
  • CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.
  • “We are delighted to welcome Kurt to CurvaFix’s Board of Directors,” said Mark Foster, CEO at CurvaFix.
  • “His extensive experience and proven track record of success in the orthopedic medical device sector makes him an invaluable addition to our board.
  • “I am honored to join CurvaFix’s excellent Board of Directors,” said Dr. Jacobus.

Spinal Non-Fusion Devices Market Poised for Growth: Global Insights and Forecast to 2030 - Escalating Prevalence of Spinal Disorders, Advanced Product Options, and Product Developments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, General Health, Surgery, Medical Devices, Health, Spine, Incidence, Competitive landscape, USD, FDA, Ageing, Growth, World Health Organization, Projection, Prevalence, Tetraplegia, Medtronic, NuVasive, Accident, Research, Medical device

The "Spinal Non-Fusion Devices Market Insights, Competitive Landscape and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spinal Non-Fusion Devices Market Insights, Competitive Landscape and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to a detailed market assessment, the Spinal Non-Fusion Devices sector was valued at a commendable USD 2,757.17 million in the year 2023.
  • The expected growth trajectory is attributed to the escalating prevalence of spinal disorders, advanced product options, and burgeoning product development endeavors.
  • With specialized segmentation ranging from product type to global geography, this comprehensive market assessment elucidates the dynamic environment of the Spinal Non-Fusion Devices market.

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, EPS, Task force, DNA, Nursing care plan, Piperacillin, Noise, Corporate social responsibility, FDA, Corporation, Medicine, UN, Dow Jones, EMR, Failure, Baxter International, Growth, Perioperative, TCFD, DJSI, Patient, Tazobactam, Centrella, Skin, Thrombin, Risk, Warburg Pincus, Acute liver failure, Galaxy, PD, NuVasive, Peritoneal dialysis, Risk management, Advent International, BPS, Sale, Eye, CST, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
  • For full-year 2023, net income attributable to Baxter on a U.S. GAAP basis totaled $2.66 billion, or $5.25 per diluted share.
  • In 2023, the company was named to the Dow Jones Sustainability Index (DJSI) North America, which has included Baxter each year since it launched in 2005.
  • For full-year 2024: Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.

Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer

Retrieved on: 
Monday, February 5, 2024
NuVasive, Growth, Pfeil, Globus, CFO, Globus Medical, Management

AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) and chief financial officer (CFO).

Key Points: 
  • AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) and chief financial officer (CFO).
  • Having served as the Company’s CFO since August 2019, in this expanded role, Pfeil will help further drive the Company's strategic roadmap through business and operational planning as well as financial performance management.
  • "With a track record of over 20 years of high-performance industry experience, including the past four years with Globus, Keith has demonstrated operational and financial leadership and a deep passion for our business," said Dan Scavilla, president and chief executive officer of Globus Medical, to whom Pfeil will continue reporting.
  • The Company expects to announce its fourth quarter and full year 2023 financial results on February 20, 2024, after the market close.

Amanda Bloom Joins Spineology as Executive Vice President of Marketing

Retrieved on: 
Tuesday, January 16, 2024
Surgery, Medical Devices, Hospitals, Marketing, Communications, Health Technology, Practice Management, Biotechnology, Health, Patient, MIS, DePuy Synthes, Clinical, Spine, Software, Education, Medical device, Medtech, Product marketing, Ultra, Johnson & Johnson, Robotics, NuVasive, Organization, Surgeon, Inc., Growth, Management

Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Amanda Bloom as Executive Vice President, Marketing.

Key Points: 
  • Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Amanda Bloom as Executive Vice President, Marketing.
  • Bloom comes to Spineology with extensive experience, having served in the Medical Device and Technology fields related to spinal implants, procedures, robotics, software, navigation, and imaging.
  • “I am thrilled to have Amanda join the executive leadership team at Spineology after having had the privilege to work with her at NuVasive,” said Brian Snider, Chief Executive Officer.
  • Most recently, Bloom served as Vice President of Marketing for two innovative start-up organizations; Avail Medsystems, and Radiaction Medical, both providing novel solutions to unique, unmet clinical needs across multiple surgical disciplines.

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

Retrieved on: 
Wednesday, January 10, 2024
Seed, Patient, Health, CFO, Spine, Enabling, Globus Medical, Globus, NuVasive

AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023.

Key Points: 
  • AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023.
  • The company anticipates fourth quarter 2023 sales of approximately $615.5 million, an increase of 124.2 percent over the fourth quarter 2022 on an as-reported basis.
  • “Excluding the impacts of the September 1, 2023 merger with NuVasive, Inc., legacy Globus fourth quarter revenue was approximately $302.9 million, an increase of 10.4 percent over the prior year fourth quarter.
  • The company expects to announce its fourth quarter and full year 2023 financial results on February 20, 2024, after the market close.

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Retrieved on: 
Wednesday, January 3, 2024
NSPR, NuVasive, TEL, Stroke, Integra, IDE, Globus Medical, Integra LifeSciences, Orthopedic surgery, Growth, Rutgers University, Patient, Compensated emancipation, Stenosis, Employment, Syracuse University, NSO, EPS, Senior

TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America. Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.

Key Points: 
  • TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.
  • Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.
  • Before that, he served as Vice President of Global Commercial Strategy at Smith+Nephew, and, prior to that, in various roles of increasing responsibility at Integra LifeSciences, culminating with Senior Vice President and General Manager - Extremity Orthopedics.
  • In connection with the appointment of Mr. Ligotti as Executive Vice President and General Manager of North America, InspireMD has granted Mr. Ligotti 138,460 shares of restricted stock and stock options to purchase 46,150 shares of InspireMD’s common stock.

Orthofix Names Massimo Calafiore as President and Chief Executive Officer

Retrieved on: 
Tuesday, November 28, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Managed Care, Sale, EBITDA, Acquisition, NYSE, Heidrick & Struggles, Interim, ENOV, Mechanical engineering, NuVasive, Spine, Surgeon, Orthopedic surgery, Elective surgery, Ankle, Patient, Multimedia, Mentorship, Sustainability Accounting Standards Board, Ellipse, MBA, University, Trauma, Growth, Knowledge, University of Catania, Management, Nursing, New York University

(NASDAQ:OFIX), a leading global spine and orthopedics company, announced today that Massimo Calafiore has been named incoming President and Chief Executive Officer.

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, announced today that Massimo Calafiore has been named incoming President and Chief Executive Officer.
  • Mr. Calafiore is currently Chief Executive Officer of LimaCorporate S.p.A., a global orthopedics company, and his appointment to Orthofix is expected to be effective in early 2024, following the completion of LimaCorporate’s previously announced acquisition by Enovis Corporation (NYSE: ENOV).
  • At that time, Mr. Calafiore is also expected to join Orthofix’s Board of Directors.
  • At the beginning of his tenure at NuVasive, Mr. Calafiore served as President of NuVasive Specialized Orthopedics (formerly Ellipse Technologies).